88 related articles for article (PubMed ID: 15627885)
21. Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer.
Yuan Z; Wang S; Ni K; Zhan Y; Ma H; Liu X; Xin R; Zhou X; Liu Z; Zhao X; Yin X; Ping H; Liu Y; Wang W; Yan S; Han Q; Cui W; Zhang X; Zhang Q; Zhang C
Med Sci Monit; 2022 Sep; 28():e937757. PubMed ID: 36117308
[TBL] [Abstract][Full Text] [Related]
22. The potential of soluble programmed death-ligand 1 (sPD-L1) as a diagnosis marker for colorectal cancer.
Shao W; Xu Y; Lin S; Gao J; Gao J; Wang H
Front Oncol; 2022; 12():988567. PubMed ID: 36052227
[TBL] [Abstract][Full Text] [Related]
23. Human chorionic gonadotropin-β promotes pancreatic cancer progression via the epithelial mesenchymal transition signaling pathway.
Uesato Y; Kawamata F; Ishino S; Ono S; Tamashiro K; Koyama H; Takatsuki M
J Gastrointest Oncol; 2022 Jun; 13(3):1384-1394. PubMed ID: 35837184
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of GDP dissociation inhibitor 1 gene associates with the invasiveness and poor outcomes of colorectal cancer.
Xie X; Lin H; Zhang X; Song P; He X; Zhong J; Shi J
Bioengineered; 2021 Dec; 12(1):5595-5606. PubMed ID: 34515625
[TBL] [Abstract][Full Text] [Related]
25. Clinical Significance and Role of TK1, CEA, CA 19-9 and CA 72-4 levels in Diagnosis of Colorectal Cancers.
Singh S; Kumar R; Kumar U; Kumari R
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3133-3136. PubMed ID: 33247667
[TBL] [Abstract][Full Text] [Related]
26. Serum microRNA-592 serves as a novel potential biomarker for early diagnosis of colorectal cancer.
Pan Z; Miao L
Oncol Lett; 2020 Aug; 20(2):1119-1126. PubMed ID: 32724351
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer.
Gao Y; Wang J; Zhou Y; Sheng S; Qian SY; Huo X
Sci Rep; 2018 Feb; 8(1):2732. PubMed ID: 29426902
[TBL] [Abstract][Full Text] [Related]
28. Quantitative proteome analysis of colorectal cancer-related differential proteins.
Zhang Y; Liu Y; Ye Y; Shen D; Zhang H; Huang H; Li S; Wang S; Ren J
J Cancer Res Clin Oncol; 2017 Feb; 143(2):233-241. PubMed ID: 27659785
[TBL] [Abstract][Full Text] [Related]
29. Comparative study of tumor markers in patients with colorectal carcinoma before and after chemotherapy.
Basu A; Seth S; Chauhan AK; Bansal N; Arora K; Mahaur A
Ann Transl Med; 2016 Feb; 4(4):71. PubMed ID: 27004218
[TBL] [Abstract][Full Text] [Related]
30. Multiplex determination of serological signatures in the sera of colorectal cancer patients using hydrogel biochips.
Butvilovskaya VI; Popletaeva SB; Chechetkin VR; Zubtsova ZI; Tsybulskaya MV; Samokhina LO; Vinnitskii LI; Ragimov AA; Pozharitskaya EI; Grigor Eva GA; Meshalkina NY; Golysheva SV; Shilova NV; Bovin NV; Zasedatelev AS; Rubina AY
Cancer Med; 2016 Jul; 5(7):1361-72. PubMed ID: 26992329
[TBL] [Abstract][Full Text] [Related]
31. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances.
Lech G; Słotwiński R; Słodkowski M; Krasnodębski IW
World J Gastroenterol; 2016 Feb; 22(5):1745-55. PubMed ID: 26855534
[TBL] [Abstract][Full Text] [Related]
32. Blood CEA levels for detecting recurrent colorectal cancer.
Nicholson BD; Shinkins B; Pathiraja I; Roberts NW; James TJ; Mallett S; Perera R; Primrose JN; Mant D
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011134. PubMed ID: 26661580
[TBL] [Abstract][Full Text] [Related]
33. A systematic review and meta-analysis of diagnostic and prognostic serum biomarkers of colorectal cancer.
Liu Z; Zhang Y; Niu Y; Li K; Liu X; Chen H; Gao C
PLoS One; 2014; 9(8):e103910. PubMed ID: 25105762
[TBL] [Abstract][Full Text] [Related]
34. Colon cancer-specific antigen-2 may be used as a detecting and prognostic marker in colorectal cancer: a preliminary observation.
Xue G; Wang X; Yang Y; Liu D; Cheng Y; Zhou J; Cao Y
PLoS One; 2014; 9(4):e94252. PubMed ID: 24710115
[TBL] [Abstract][Full Text] [Related]
35. Circulating and stool nucleic acid analysis for colorectal cancer diagnosis.
De Maio G; Rengucci C; Zoli W; Calistri D
World J Gastroenterol; 2014 Jan; 20(4):957-67. PubMed ID: 24574768
[TBL] [Abstract][Full Text] [Related]
36. Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis).
Bagaria B; Sood S; Sharma R; Lalwani S
Cancer Biol Med; 2013 Sep; 10(3):148-57. PubMed ID: 24379990
[TBL] [Abstract][Full Text] [Related]
37. Negative prognostic factors in colorectal carcinoma: An analysis of 448 patients.
Caliskan C; Guler N; Karaca C; Makay O; Firat O; Korkut MA
Indian J Surg; 2010 Jun; 72(3):243-8. PubMed ID: 23133256
[TBL] [Abstract][Full Text] [Related]
38. Total mesorectal excision for rectal cancer in an unselected population: quality assessment in a low volume center.
Ferenschild FT; Dawson I; de Wilt JH; de Graaf EJ; Groenendijk RP; Tetteroo GW
Int J Colorectal Dis; 2009 Aug; 24(8):923-9. PubMed ID: 19488771
[TBL] [Abstract][Full Text] [Related]
39. A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy.
Zlobec I; Vuong T; Hayashi S; Haegert D; Tornillo L; Terracciano L; Lugli A; Jass J
Br J Cancer; 2007 Mar; 96(5):793-800. PubMed ID: 17311026
[TBL] [Abstract][Full Text] [Related]
40. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer.
Zlobec I; Steele R; Terracciano L; Jass JR; Lugli A
J Clin Pathol; 2007 Oct; 60(10):1112-6. PubMed ID: 17182662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
